What is uprifosbuvir (MK-3682) and why is it being impaired?

Uprifosbuvir (MK-3682) is a drug candidate developed by Merck for the treatment of hepatitis C virus (HCV) infection. The impairment charge was triggered by recent changes in its product profile, Merck's expectations for its pricing, and the overall market opportunity, which led to a reassessment of the intangible asset's fair value.

How does this impairment affect Merck's reported earnings?

The $2.9 billion pre-tax impairment charge significantly impacted Merck's reported Generally Accepted Accounting Principles (GAAP) earnings for 2016. It lowered the fourth-quarter 2016 GAAP diluted EPS from $0.42 to a net loss of $0.22 and reduced the full-year 2016 GAAP EPS from $2.04 to $1.41. However, Merck's non-GAAP EPS, which excludes certain items like impairments, remains unaffected.

What is the financial impact of this impairment on Merck's balance sheet?

The impairment charge directly reduces the carrying value of the intangible asset related to uprifosbuvir on Merck's balance sheet. The fair value was assessed to be $240 million, resulting in the $2.9 billion pre-tax charge. Merck will continue to monitor this remaining $240 million asset for potential further impairments.

What does this mean for Merck's hepatitis C business going forward?

Merck is still evaluating its options for the uprifosbuvir clinical development program. While this specific asset faced an impairment, the company's overall strategy and other hepatitis C assets may be unaffected. Investors should look for future updates on the company's HCV pipeline and strategic decisions regarding uprifosbuvir.

MRK 8-K: Financial Events

Summary

Merck & Co., Inc. (MRK) announced a significant event impacting its 2016 financial results via an 8-K filing on February 23, 2017. The company has recognized a substantial pre-tax intangible asset impairment charge of $2.9 billion ($1.9 billion after taxes) related to its hepatitis C virus (HCV) drug candidate, uprifosbuvir (MK-3682). This charge stems from recent shifts in the product profile, pricing expectations, and the overall market opportunity for uprifosbuvir, which was acquired in the 2014 purchase of Idenix Pharmaceuticals. The impairment charge has a notable impact on Merck's reported 2016 earnings per share (EPS). Specifically, fourth-quarter 2016 GAAP diluted EPS was revised downwards from $0.42 to a loss of $0.22, and full-year 2016 GAAP EPS decreased from $2.04 to $1.41. While these GAAP figures were affected, Merck emphasized that its non-GAAP EPS for both periods remains unchanged. The company is currently assessing the future of the uprifosbuvir clinical development program and will continue to monitor the remaining $240 million intangible asset value for potential further impairments.

Key Highlights

1Merck recorded a $2.9 billion pre-tax ($1.9 billion after-tax) intangible asset impairment charge related to uprifosbuvir (MK-3682), an HCV drug candidate.
2The impairment is attributed to changes in the product profile, pricing expectations, and market opportunity for uprifosbuvir.
3Uprifosbuvir was originally acquired through the 2014 acquisition of Idenix Pharmaceuticals.
4The impairment charge reduced reported fourth-quarter 2016 GAAP diluted EPS from $0.42 to a loss of $0.22.
5Full-year 2016 GAAP EPS was reduced from $2.04 to $1.41 due to the impairment.
6Merck's non-GAAP EPS for the fourth quarter and full year 2016 remain unchanged.
7The company is still evaluating options for the uprifosbuvir development program and will monitor the remaining $240 million intangible asset.

Merck & Co., Inc. 8-K Report, Material Impairment (Feb 23, 2017)

Summary

Key Highlights

Frequently Asked Questions